New Delhi: Oxford’s coronavirus vaccine, which is considered to be the most advanced formula against fighting COVID-19, has been started to be manufactured at Serum Institute of India (SII) in Pune. The coronavirus pandemic has affected over 15 million people in the entire world.
The initial trials of the vaccine published by Oxford showed very promising results in the process of recovery in humans who were infected with novel coronavirus. The vaccine is now undergoing thrid phase of human clinical trials.
The Pune-based SII has already started manufacturing the Oxford’s COVID-19 vaccine ‘Covishield’ for use in India, SII’s executive director Suresh Jadhav while speaking to The Hindu said that the company is looking to manufacture 20 to 30 lakh doses by the end of August.
SII is looking to manufacture the vaccines in proportion to the commercial requirement of the phase 3 human trials.
A few weeks ago, SII’s CEO Adar Poonawalla had confirmed that the company would manufacture atleast 100 crore doses of the Oxford vaccine to help cater the needs of the medication in India and other low-income countries.
“Serum Institute of India has entered a manufacturing partnership with AstraZeneca to produce and supply 1 billion doses of the Covid-19 vaccine being developed by Oxford University. These vaccines will be for India and middle and low-income countries across the world (GAVI countries),” Adar Poonawalla told the media.
The company has also confirmed that the price of Oxford’s coronavirus vaccine ‘Covishield’ will be capped at Rs 1,000 per dose. The price has been kept comparatively low keeping in mind the needy people from all sects and classes.